Accredited Investors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $247K | Sell |
3,673
-704
| -16% | -$46.9K | 0.01% | 264 |
|
|
2026
Q1 | $275K | Hold |
4,377
| – | – | 0.01% | 229 |
|
|
2025
Q4 | $291K | Hold |
4,377
| – | – | 0.02% | 225 |
|
|
2025
Q3 | $295K | Hold |
4,377
| – | – | 0.02% | 202 |
|
|
2025
Q2 | $382K | Hold |
4,377
| – | – | 0.02% | 160 |
|
|
2025
Q1 | $299K | Hold |
4,377
| – | – | 0.02% | 176 |
|
|
2024
Q4 | $340K | Sell |
4,377
-130
| -3% | -$9.63K | 0.02% | 169 |
|
|
2024
Q3 | $302K | Hold |
4,507
| – | – | 0.02% | 176 |
|
|
2024
Q2 | $511K | Sell |
4,507
-136
| -3% | -$17.2K | 0.03% | 121 |
|
|
2024
Q1 | $644K | Buy |
4,643
+130
| +3% | +$16.3K | 0.04% | 109 |
|
|
2023
Q4 | $560K | Hold |
4,513
| – | – | 0.04% | 114 |
|
|
2023
Q3 | $421K | Hold |
4,513
| – | – | 0.03% | 124 |
|
|
2023
Q2 | $580K | Sell |
4,513
-389
| -8% | -$47K | 0.04% | 102 |
|
|
2023
Q1 | $570K | Hold |
4,902
| – | – | 0.04% | 101 |
|
|
2022
Q4 | $555K | Buy |
4,902
+2
| +0% | +$220 | 0.05% | 98 |
|
|
2022
Q3 | $395K | Sell |
4,900
-100
| -2% | -$8.47K | 0.05% | 111 |
|
|
2022
Q2 | $373K | Sell |
5,000
-8
| -0.2% | -$730 | 0.04% | 118 |
|
|
2022
Q1 | $641K | Buy |
5,008
+16
| +0.3% | +$1.75K | 0.06% | 96 |
|
|
2021
Q4 | $670K | Hold |
4,992
| – | – | 0.06% | 96 |
|
|
2021
Q3 | $682K | Sell |
4,992
-108
| -2% | -$13.6K | 0.07% | 86 |
|
|
2021
Q2 | $544K | Sell |
5,100
-228
| -4% | -$21.9K | 0.06% | 101 |
|
|
2021
Q1 | $479K | Sell |
5,328
-1,012
| -16% | -$95K | 0.06% | 99 |
|
|
2020
Q4 | $586K | Hold |
6,340
| – | – | 0.1% | 86 |
|
|
2020
Q3 | $653K | Sell |
6,340
-284
| -4% | -$29.7K | 0.14% | 72 |
|
|
2020
Q2 | $671K | Sell |
6,624
-464
| -7% | -$41.5K | 0.14% | 70 |
|
|
2020
Q1 | $477K | Sell |
7,088
-1,616
| -19% | -$101K | 0.11% | 80 |
|
|
2019
Q4 | $476K | Hold |
8,704
| – | – | 0.08% | 88 |
|
|
2019
Q3 | $325K | Hold |
8,704
| – | – | 0.06% | 105 |
|
|
2019
Q2 | $326K | Sell |
8,704
-500
| -5% | -$15.7K | 0.06% | 105 |
|
|
2019
Q1 | $274K | Buy |
9,204
+772
| +9% | +$27.1K | 0.06% | 110 |
|
|
2018
Q4 | $253K | Sell |
8,432
-1,036
| -11% | -$32.9K | 0.06% | 104 |
|
|
2018
Q3 | $339K | Hold |
9,468
| – | – | 0.08% | 85 |
|
|
2018
Q2 | $225K | Buy |
+9,468
| New | +$201K | 0.06% | 105 |
|
|
2017
Q2 | – | Sell |
-9,468
| Closed | -$201K | – | 110 |
|
|
2017
Q1 | $201K | Buy |
+9,468
| New | +$185K | 0.05% | 103 |
|
|
2016
Q4 | – | Sell |
-9,468
| Closed | -$207K | – | 100 |
|
|
2016
Q3 | $207K | Buy |
+9,468
| New | +$211K | 0.06% | 91 |
|
|
2015
Q4 | – | Sell |
-9,468
| Closed | -$204K | – | 91 |
|
|
2015
Q3 | $204K | Buy |
+9,468
| New | +$211K | 0.05% | 80 |
|
Other funds holding DXCM
SIMG
CC
FFM
PCM
FMI
Accredited Investors's DXCM Position: Q2 2026 in Review
Accredited Investors reduced its DexCom (DXCM) stake by 16% in Q2 2026, selling an estimated $46.9K and leaving 3,673 shares worth $247K. The position accounts for 0.01% of the portfolio, ranked #264.
Accredited Investors first reported a position in DXCM in Q3 2015 and has held it in 36 quarters since. The position peaked at $682K in Q3 2021. 353 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Accredited Investors held 3,673 shares of DexCom worth $247K as of Q2 2026.
- Accredited Investors sold 704 DexCom shares in Q2 2026, an estimated $46.9K.
- DexCom made up 0.01% of Accredited Investors's portfolio in Q2 2026, its #264 holding.
- Accredited Investors first reported a position in DexCom in Q3 2015 and has held it in 36 quarters since.
- Accredited Investors's DexCom position peaked at $682K in Q3 2021.
- 353 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.